scyllo-Inositol (also known as scyllitol) is a cyclohexanehexol, a stereoisomer of the more common myo‑inositol. Its molecular formula is C₆H₁₂O₆, and it possesses six hydroxyl (–OH) groups attached to a cyclohexane ring in a specific configuration that distinguishes it from other inositol isomers. The compound is one of the eight possible stereoisomers of inositol.
Chemical and Physical Properties
- Molecular weight: 180.16 g·mol⁻¹
- Solubility: Highly soluble in water; limited solubility in organic solvents such as ethanol.
- Physical state: Typically obtained as a crystalline solid at ambient temperature.
Natural Occurrence
scyllo‑Inositol is present in relatively low concentrations in various plant species and can be isolated from certain botanical extracts. It is not a major component of human or animal metabolism under normal physiological conditions.
Research and Clinical Use
The compound has attracted scientific interest primarily for its potential neuroprotective effects. In preclinical studies, scyllo‑inositol demonstrated the ability to bind amyloid‑β oligomers, reducing their aggregation, which is a hallmark of Alzheimer’s disease pathology. Based on these findings, it progressed to early‑phase clinical trials (Phase II) as an investigational drug for the treatment of Alzheimer’s disease. As of the latest publicly available data, the outcomes of these trials have not established scyllo‑inositol as an approved therapeutic agent.
Safety and Toxicology
Toxicological assessments in animal models have indicated a relatively high tolerable dose, but human safety data remain limited to controlled clinical trial settings. Adverse effects reported in trials have included gastrointestinal discomfort at higher dosages; no severe toxicity has been conclusively linked to the compound when administered within trial parameters.
Regulatory Status
scyllo‑Inositol is not approved as a prescription medication in major regulatory jurisdictions (e.g., FDA, EMA). It may be available as a research chemical or dietary supplement in some markets, subject to local regulations.
References
- Standard chemical reference works (e.g., IUPAC nomenclature, chemical abstracts).
- Peer‑reviewed studies on amyloid‑β interaction and Alzheimer’s disease clinical trials.
- Safety data sheets from reputable chemical suppliers.
All information presented is based on publicly available encyclopedic and peer‑reviewed sources up to the knowledge cutoff date.
